Application and prospect of immunological detection technology for active pulmonary tuberculosis

doi:10.19983/j.issn.2096-8493.20210112

Abstract

Abstract:

Tuberculosis is an infectious disease that seriously endangers human health. Active pulmonary tuberculosis is diagnosed by etiological detection in clinic, however, it is difficult to identify the active pulmonary tuberculosis with negative etiology. With the development of immunological detection technology, more and more new detection methods to determine the activity of pulmonary tuberculosis are proposed. This paper reviews the application of immunological detection techniques in active pulmonary tuberculosis from cellular immunity, cytokine detection and humoral immunity.

Key words: Tuberculosis,pulmonary, Diagnosis, Immunologic techniques, Review literature as topic

CLC Number:

R52
R392

LIU Hui-min, TIAN Yao, BEI Cheng-li, FU Man-jiao. Application and prospect of immunological detection technology for active pulmonary tuberculosis[J]. Journal of Tuberculosis and Lung Disease , 2022, 3(1): 70-74. doi: 10.19983/j.issn.2096-8493.20210112

References 42

[1]	中华人民共和国国家卫生和计划生育委员会. WS 288—2017 肺结核诊断. 2017-11-09.
[2]	Boehme CC, Saacks S, O’Brien RJ. The changing landscape of diagnostic services for tuberculosis. Semin Respir Crit Care Med, 2013, 34(1):17-31. doi: 10.1055/s-0032-1333468. doi: 10.1055/s-0032-1333468 URL
[3]	Ryu YJ. Diagnosis of pulmonary tuberculosis: recent advances and diagnostic algorithms. Tuberc Respir Dis (Seoul), 2015, 78(2):64-71. doi: 10.4046/trd.2015.78.2.64. doi: 10.4046/trd.2015.78.2.64 URL
[4]	To KW, Kam KM, Chan DPC, et al. Utility of GeneXpert in analysis of bronchoalveolar lavage samples from patients with suspected tuberculosis in an intermediate-burden setting. J Infect, 2018, 77(4):296-301. doi: 10.1016/j.jinf.2018.06.011. doi: 10.1016/j.jinf.2018.06.011 URL
[5]	Nakajima T, Yasufuku K, Fujiwara T, et al. Recent advances in endobronchial ultrasound-guided transbronchial needle aspiration. Respir Investig, 2016, 54(4):230-236. doi: 10.1016/j.resinv.2016.02.002. doi: 10.1016/j.resinv.2016.02.002 URL
[6]	付亮, 邓国防. 实验室检测技术在肺结核活动性判断中的应用进展. 中国防痨杂志, 2020, 42(6):626-629. doi: 10.3969/j.issn.1000-6621.2020.06.016. doi: 10.3969/j.issn.1000-6621.2020.06.016
[7]	国家感染性疾病临床医学研究中心, 深圳市第三人民医院, 《中国防痨杂志》编辑委员会. 肺结核活动性判断规范及临床应用专家共识. 中国防痨杂志, 2020, 42(4):301-307. doi: 10.3969/j.issn.1000-6621.2020.04.001. doi: 10.3969/j.issn.1000-6621.2020.04.001
[8]	Auld SC, Click ES, Heilig CM, et al. Association between tuberculin skin test result and clinical presentation of tuberculosis disease. BMC Infect Dis, 2013, 13:460. doi: 10.1186/1471-2334-13-460. doi: 10.1186/1471-2334-13-460 URL
[9]	张薇, 赵立. 结核分枝杆菌感染的实验室诊断方法及检测技术研究进展. 国际呼吸杂志, 2019, 39(20):1586-1591. doi: 10.3760/cma.j.issn.1673-436X.2019.20.014. doi: 10.3760/cma.j.issn.1673-436X.2019.20.014
[10]	Liu Z, Qie S, Li L, et al. Identification of Novel RD1 Antigens and Their Combinations for Diagnosis of Sputum Smear-/Culture+TB Patients. Biomed Res Int, 2016, 2016:7486425. doi: 10.1155/2016/7486425. doi: 10.1155/2016/7486425
[11]	Ren N, JinLi J, Chen Y, et al. Identification of new diagnostic biomarkers for Mycobacterium tuberculosis and the potential application in the serodiagnosis of human tuberculosis. Microb Biotechnol, 2018, 11(5):893-904. doi: 10.1111/1751-7915.13291. doi: 10.1111/1751-7915.13291 URL
[12]	Furin J, Cox H, Pai M. Tuberculosis. Lancet, 2019, 393(10181):1642-1656. doi: 10.1016/S0140-6736(19)30308-3. doi: 10.1016/S0140-6736(19)30308-3 URL
[13]	吴琼, 王堃, 丘世飏, 等. T细胞斑点试验在结核感染诊断中的临床应用. 中国医师杂志, 2018, 20(1):87-91. doi: 10.3760/cma.j.issn.1008-1372.2018.01.022. doi: 10.3760/cma.j.issn.1008-1372.2018.01.022
[14]	Zhang L, Shi X, Zhang Y, et al. Analysis of Factors Influencing Diagnostic Accuracy of T-SPOT.TB for Active Tuberculosis in Clinical Practice. Sci Rep, 2017, 7(1):7764. doi: 10.1038/s41598-017-07785-6. doi: 10.1038/s41598-017-07785-6 URL
[15]	中华医学会结核病学分会, 《中华结核和呼吸杂志》编辑委员会. γ-干扰素释放试验在中国应用的建议. 中华结核和呼吸杂志, 2014, 37(10):744-747. doi: 10.3760/cma.j.issn.1001-0939.2014.10.011. doi: 10.3760/cma.j.issn.1001-0939.2014.10.011
[16]	Wlodarczyk M, Rudnicka W, Janiszewska-Drobinska B, et al. Interferon-gamma assay in combination with tuberculin skin test are insufficient for the diagnosis of culture-negative pulmonary tuberculosis. PLoS One, 2014, 9(9):e107208. doi: 10.1371/journal.pone.0107208. doi: 10.1371/journal.pone.0107208 URL
[17]	Li G, Li F, Zhao HM, et al. Evaluation of a New IFN-γ Release Assay for Rapid Diagnosis of Active Tuberculosis in a High-Incidence Setting. Front Cell Infect Microbiol, 2017, 7:117. doi: 10.3389/fcimb.2017.00117. doi: 10.3389/fcimb.2017.00117
[18]	王婷, 谭耀驹, 吴士及, 等. 结核感染T细胞斑点试验中结核特异性抗原和植物血凝素比值对活动性结核的诊断价值. 中华结核和呼吸杂志, 2019, 42(4):262-267. doi: 10.3760/cma.j.issn.1001-0939.2019.04.003. doi: 10.3760/cma.j.issn.1001-0939.2019.04.003
[19]	Wang F, Hou H, Zhou H, et al. Use of TBAg/PHA ratio in distinguishing tuberculoma from cancer in solitary pulmonary nodule or mass. Clin Respir J, 2018, 12(3):1174-1181. doi: 10.1111/crj.12648. doi: 10.1111/crj.12648 URL
[20]	Wang F, Yu J, Zhou Y, et al. The Use of TB-Specific Antigen/Phytohemagglutinin Ratio for Diagnosis and Treatment Monitoring of Extrapulmonary Tuberculosis. Front Immunol, 2018, 9:1047. doi: 10.3389/fimmu.2018.01047. doi: 10.3389/fimmu.2018.01047 URL
[21]	Bosco MJ, Hou H, Mao L, et al. The performance of the TBAg/PHA ratio in the diagnosis of active TB disease in immunocompromised patients. Int J Infect Dis, 2017, 59:55-60. doi: 10.1016/j.ijid.2017.03.025. doi: 10.1016/j.ijid.2017.03.025 URL
[22]	Luo Y, Tang G, Lin Q, et al. Combination of mean spot sizes of ESAT-6 spot-forming cells and modified tuberculosis-specific antigen/phytohemagglutinin ratio of T-SPOT.TB assay in distinguishing between active tuberculosis and latent tuberculosis infection. J Infect, 2020, 81(1):81-89. doi: 10.1016/j.jinf.2020.04.038. doi: 10.1016/j.jinf.2020.04.038 URL
[23]	Goletti D, Butera O, Bizzoni F, et al. Region of difference 1 antigen-specific CD4⁺ memory T cells correlate with a favorable outcome of tuberculosis. J Infect Dis, 2006, 194(7):984-992. doi: 10.1086/507427. doi: 10.1086/507427 pmid: 16960787
[24]	Petruccioli E, Vanini V, Chiacchio T, et al. Analytical evaluation of QuantiFERON-Plus and QuantiFERON-Gold In-tube assays in subjects with or without tuberculosis. Tuberculosis (Edinb), 2017, 106:38-43. doi: 10.1016/j.tube.2017.06.002. doi: 10.1016/j.tube.2017.06.002 URL
[25]	Denkinger CM, Pai M, Patel M, et al. Gamma interferon release assay for monitoring of treatment response for active tuberculosis: an explosion in the spaghetti factory. J Clin Microbiol, 2013, 51(2):607-610. doi: 10.1128/JCM.02278-12. doi: 10.1128/JCM.02278-12 pmid: 23175268
[26]	Wu J, Wang S, Lu C, et al. Multiple cytokine responses in discriminating between active tuberculosis and latent tuberculosis infection. Tuberculosis (Edinb), 2017, 102:68-75. doi: 10.1016/j.tube.2016.06.001. doi: 10.1016/j.tube.2016.06.001 URL
[27]	Guo SJ, Jia LQ, Hu QJ, et al. Diagnostic accuracy of interferon gamma-induced protein 10 for tuberculosis: a meta-analysis. Int J Clin Exp Med, 2014, 7(1):93-100.
[28]	Luo J, Zhang M, Yan B, et al. Diagnostic performance of plasma cytokine biosignature combination and MCP-1 as individual biomarkers for differentiating stages Mycobacterium tuberculosis infection. J Infect, 2019, 78(4):281-291. doi: 10.1016/j.jinf.2018.10.017. doi: 10.1016/j.jinf.2018.10.017 URL
[29]	余艳艳, 谭云洪, 朱权, 等. INF-γ和IL-2联合检测在结核病辅助诊断中的价值. 检验医学与临床, 2019, 16(11):1477-1479, 1482. doi: 10.3969/j.issn.1672-9455.2019.11.002. doi: 10.3969/j.issn.1672-9455.2019.11.002
[30]	Correia-Neves M, Fröberg G, Korshun L, et al. Biomarkers for tuberculosis: the case for lipoarabinomannan. ERJ Open Res, 2019, 5(1):00115-2018. doi: 10.1183/23120541.00115-2018. doi: 10.1183/23120541.00115-2018
[31]	Zhou KL, Li X, Zhang XL, et al. Mycobacterial mannose-capped lipoarabinomannan: a modulator bridging innate and adaptive immunity. Emerg Microbes Infect, 2019, 8(1):1168-1177. doi: 10.1080/22221751.2019.1649097. doi: 10.1080/22221751.2019.1649097 URL
[32]	Kerkhoff AD, Longley N, Kelly N, et al. Determine TB-LAM point-of-care tuberculosis assay predicts poor outcomes in outpatients during their first year of antiretroviral therapy in South Africa. BMC Infect Dis, 2020, 20(1):555. doi: 10.1186/s12879-020-05227-9. doi: 10.1186/s12879-020-05227-9 pmid: 32736601
[33]	Mathabire Rucker SC, Cossa L, Harrison RE, et al. Feasibility of using Determine TB-LAM to diagnose tuberculosis in HIV-positive patients in programmatic conditions: a multisite study. Glob Health Action, 2019, 12(1):1672366. doi: 10.1080/16549716.2019.1672366. doi: 10.1080/16549716.2019.1672366 URL
[34]	孙卫国, 曹志红, 李改平, 等. 结核分枝杆菌Rv2660c蛋白原核重组表达及其免疫活性研究. 临床肺科杂志, 2020, 25(2):167-171. doi: 10.3969/j.issn.1009-6663.2020.02.002. doi: 10.3969/j.issn.1009-6663.2020.02.002
[35]	刘永亮. 活动性结核标志物的筛选和初步评价. 厦门: 厦门大学, 2018.
[36]	唐洁, 陈策, 查成, 等. 基于结核杆菌耐热抗原小分子多肽刺激人外周血T细胞产生TNF-α和IFN-γ鉴别肺结核和潜伏性结核感染. 南方医科大学学报, 2017, 37(11):1442-1447. doi: 10.3969/j.issn.1673-4254.2017.11.03. doi: 10.3969/j.issn.1673-4254.2017.11.03
[37]	Shi SD, Hsueh PR, Yang PC, et al. Use of DosR Dormancy Antigens from Mycobacterium tuberculosis for Serodiagnosis of Active and Latent Tuberculosis. ACS Infect Dis, 2020, 6(2):272-280. doi: 10.1021/acsinfecdis.9b00329. doi: 10.1021/acsinfecdis.9b00329 URL
[38]	张冬, 王心愿, 蒋宁. 血清结核抗体检测对临床上诊断结核病的意义研究. 中国实用医药, 2019, 14(10):27-28. doi: 10.14163/j.cnki.11-5547/r.2019.10.011. doi: 10.14163/j.cnki.11-5547/r.2019.10.011
[39]	罗风, 李晓非. 结核病免疫学实验室检测技术新进展. 临床检验杂志, 2020, 38(1):52-55. doi: 10.13602/j.cnki.jcls.2020.01.14. doi: 10.13602/j.cnki.jcls.2020.01.14
[40]	Cao SH, Chen YQ, Sun Y, et al. Screening of Serum Biomarkers for Distinguishing between Latent and Active Tuberculosis Using Proteome Microarray. Biomed Environ Sci, 2018, 31(7):515-526. doi: 10.3967/bes2018.069. doi: 10.3967/bes2018.069
[41]	逄宇, 王玉峰, 高兴辉, 等. 结核分枝杆菌实验室检测产品和技术应用进展. 中国临床新医学, 2021, 14(1):23-34. doi: 10.3969/j.issn.1674-3806.2021.01.05. doi: 10.3969/j.issn.1674-3806.2021.01.05
[42]	Warsinske HC, Rao AM, Moreira FMF, et al. Assessment of Validity of a Blood-Based 3-Gene Signature Score for Progression and Diagnosis of Tuberculosis, Disease Severity, and Treatment Response. JAMA Netw Open, 2018, 1(6):e183779. doi: 10.1001/jamanetworkopen.2018.3779. doi: 10.1001/jamanetworkopen.2018.3779 URL